See more : Nissan Tokyo Sales Holdings Co., Ltd. (8291.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cerus Corporation (CERS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerus Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Quadrant Televentures Limited (QUADRANT.BO) Income Statement Analysis – Financial Results
- Core Scientific, Inc. (CORZW) Income Statement Analysis – Financial Results
- Goldcliff Resource Corporation (GCN.V) Income Statement Analysis – Financial Results
- Advent Technologies Holdings, Inc. (ADNWW) Income Statement Analysis – Financial Results
- HOB Biotech Group Corp.,Ltd (688656.SS) Income Statement Analysis – Financial Results
Cerus Corporation (CERS)
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.37M | 162.05M | 130.86M | 91.92M | 74.65M | 60.91M | 43.57M | 37.18M | 34.22M | 36.50M | 39.66M | 36.70M | 33.04M | 23.11M | 17.98M | 16.51M | 11.04M | 35.58M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 1.85M | 2.40M | 2.90M | 6.90M |
| Cost of Revenue | 69.97M | 74.95M | 63.48M | 41.16M | 33.42M | 31.63M | 22.53M | 20.30M | 23.46M | 21.18M | 22.60M | 20.62M | 18.54M | 12.05M | 12.58M | 9.67M | 5.23M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -634.00K | -600.00K | -700.00K | -700.00K |
| Gross Profit | 86.40M | 87.09M | 67.38M | 50.76M | 41.23M | 29.27M | 21.04M | 16.89M | 10.76M | 15.33M | 17.06M | 16.08M | 14.51M | 11.06M | 5.40M | 6.84M | 5.82M | 34.04M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 2.49M | 3.00M | 3.60M | 7.60M |
| Gross Profit Ratio | 55.25% | 53.75% | 51.49% | 55.23% | 55.23% | 48.06% | 48.29% | 45.42% | 31.44% | 41.99% | 43.01% | 43.82% | 43.91% | 47.87% | 30.04% | 41.43% | 52.66% | 95.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 134.25% | 125.00% | 124.14% | 110.14% |
| Research & Development | 67.64M | 64.11M | 63.69M | 64.41M | 60.38M | 42.56M | 33.71M | 31.32M | 25.64M | 21.69M | 15.19M | 7.60M | 7.18M | 5.20M | 6.37M | 10.21M | 14.96M | 29.51M | 24.13M | 27.65M | 52.48M | 56.42M | 48.25M | 34.82M | 22.50M | 29.80M | 19.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.84M | 52.41M | 48.75M | 45.99M | 37.73M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.52M | 83.34M | 81.29M | 67.02M | 66.21M | 56.84M | 52.41M | 48.75M | 45.99M | 37.79M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Other Expenses | 0.00 | -26.27M | -28.66M | -22.33M | -19.13M | 1.75M | 3.86M | -1.28M | 71.00K | 130.00K | 266.00K | 31.00K | 202.00K | 67.00K | 155.00K | 0.00 | 9.45M | 0.00 | 0.00 | 2.86M | 0.00 | 0.00 | 0.00 | 634.00K | 600.00K | 700.00K | 700.00K |
| Operating Expenses | 115.34M | 121.18M | 116.32M | 109.10M | 107.46M | 84.26M | 78.57M | 78.19M | 71.83M | 59.68M | 45.35M | 33.38M | 30.43M | 26.84M | 28.39M | 37.37M | 48.98M | 43.52M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 42.62M | 27.90M | 34.30M | 23.50M |
| Cost & Expenses | 185.30M | 196.13M | 179.80M | 150.25M | 140.88M | 115.90M | 101.10M | 98.48M | 95.30M | 80.85M | 67.96M | 54.00M | 48.97M | 38.89M | 40.97M | 47.04M | 54.21M | 45.06M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 41.98M | 27.30M | 33.60M | 22.80M |
| Interest Income | 0.00 | 5.83M | 4.92M | 3.75M | 6.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.39M | 5.83M | 4.92M | 3.75M | 6.07M | 4.01M | 3.02M | 2.45M | 1.71M | 599.00K | 520.00K | 551.00K | 964.00K | 689.00K | 302.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.60M | 4.56M | 4.57M | 4.46M | 2.40M | 1.45M | 1.81M | 1.82M | 202.00K | 202.00K | 202.00K | 202.00K | 922.00K | 845.00K | 915.00K | 651.00K | 774.00K | 716.00K | 652.00K | 2.15M | 3.29M | 2.50M | 1.19M | 634.00K | 600.00K | 700.00K | 700.00K |
| EBITDA | -26.54M | -34.08M | -45.99M | -51.37M | -64.61M | -51.88M | -51.87M | -58.47M | -56.14M | -36.55M | -42.04M | -14.38M | -15.10M | -15.38M | -22.92M | -28.53M | -43.17M | -4.06M | -8.69M | -23.01M | -50.54M | -56.78M | -52.69M | -39.51M | -24.29M | -30.00M | -15.20M |
| EBITDA Ratio | -16.97% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -131.58% | -163.91% | -177.66% | -120.94% | -70.85% | -46.59% | -45.40% | -64.61% | -123.18% | -181.01% | -298.28% | -24.63% | -126.29% | -136.45% | -522.96% | -668.79% | -1,161.74% | -2,133.93% | -1,012.50% | -1,075.86% | -237.68% |
| Operating Income | -30.05M | -34.08M | -48.94M | -58.33M | -66.23M | -54.99M | -57.53M | -61.45M | -61.08M | -44.35M | -28.30M | -17.30M | -15.92M | -15.96M | -23.83M | -30.53M | -43.17M | -9.48M | -9.34M | -26.83M | -53.84M | -59.28M | -53.88M | -40.13M | -24.90M | -30.70M | -15.90M |
| Operating Income Ratio | -19.22% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -132.05% | -165.26% | -178.46% | -121.49% | -71.36% | -47.15% | -48.19% | -69.06% | -132.54% | -184.95% | -390.85% | -26.64% | -38.33% | -192.84% | -557.01% | -698.20% | -1,188.05% | -2,168.18% | -1,037.50% | -1,058.62% | -230.43% |
| Total Other Income/Expenses | -7.27M | -8.26M | -5.12M | -1.24M | -4.76M | -2.35M | 832.00K | -1.28M | 1.54M | 5.94M | -14.82M | 1.63M | -1.06M | -953.00K | -302.00K | 1.35M | 4.07M | 4.70M | 22.41M | -4.33M | -4.43M | 2.09M | 4.61M | 4.10M | 0.00 | 1.20M | 1.20M |
| Income Before Tax | -37.32M | -42.34M | -54.06M | -59.57M | -70.98M | -57.34M | -56.70M | -62.73M | -59.54M | -38.37M | -43.12M | -15.68M | -16.98M | -16.91M | -24.67M | 0.00 | -52.62M | -4.78M | 12.75M | -31.15M | -4.43M | -57.19M | -49.27M | -36.03B | 0.00 | -29.50M | -14.70M |
| Income Before Tax Ratio | -23.87% | -26.13% | -41.31% | -64.81% | -95.09% | -94.13% | -130.14% | -168.71% | -173.97% | -105.12% | -108.73% | -42.72% | -51.39% | -73.18% | -137.21% | 0.00% | -476.42% | -13.43% | 52.31% | -223.95% | -45.86% | -673.64% | -1,086.37% | -1,946,682.93% | 0.00% | -1,017.24% | -213.04% |
| Income Tax Expense | 325.00K | 488.00K | 319.00K | 284.00K | 263.00K | 229.00K | 3.89M | 175.00K | -3.67M | 195.00K | 218.00K | 242.00K | 964.00K | 689.00K | 228.00K | -1.35M | 2.14M | 0.00 | -22.41M | 7.19M | 53.84M | 0.00 | 100.00K | 4.10B | -2.30M | -1.10M | -1.20M |
| Net Income | -37.49M | -42.83M | -54.38M | -59.86M | -71.24M | -57.56M | -60.59M | -62.91M | -55.87M | -38.57M | -43.34M | -15.92M | -16.98M | -16.91M | -24.14M | -29.18M | -45.30M | -4.78M | 13.06M | -31.15M | -58.27M | -57.19M | -49.37M | -36.03M | -22.60M | -29.60M | -14.70M |
| Net Income Ratio | -23.98% | -26.43% | -41.55% | -65.12% | -95.44% | -94.51% | -139.06% | -169.18% | -163.25% | -105.65% | -109.28% | -43.38% | -51.39% | -73.18% | -134.22% | -176.78% | -410.21% | -13.43% | 53.60% | -223.95% | -602.87% | -673.64% | -1,088.58% | -1,946.68% | -941.67% | -1,020.69% | -213.04% |
| EPS | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.52 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.18 | 0.58 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| EPS Diluted | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.50 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.17 | 0.55 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| Weighted Avg Shares Out | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 130.83M | 108.19M | 101.46M | 96.07M | 74.77M | 67.57M | 54.52M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 26.87M | 22.35M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
| Weighted Avg Shares Out (Dil) | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 131.66M | 108.22M | 101.83M | 96.91M | 76.53M | 67.57M | 55.06M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 28.61M | 23.95M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
Cerus Corporation Celebrates World Blood Donor Day 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the...
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th. ABOUT CERUS Cerus Corporation is dedicated solely...
Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin...
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at...
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set...
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy...
Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice President Finance and...
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %): Three...
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and...
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD...
Source: https://incomestatements.info
Category: Stock Reports